Photos
Posts

Breaking News from Amgen, Platinum Sponsor of the 3rd World Congress on Clinical Lipidology.

Amgen announced top-line results of a study that found patients with atherosclerotic cardiovascular disease who received evolocumab (Repatha) had a reduced risk of cardiovascular events, which was the trial’s primary endpoint.

It is not too late to register - book your spot now...
www.clinical-lipidology.com

See More
Amgen announced on Feb. 2 top-line results of a study that found patients with atherosclerotic cardiovascular disease who received evolocumab (Repatha) had a reduced risk of cardiovascular events, which was the trial’s primary endpoint.
cardiovascularbusiness.com

Discover the Latest Developments on Lipid Management in Diabesity and Chronic Renal Disease at the 3rd World Congress on Clinical Lipidology.

Outstanding presentations will be given by Richard O'Brien, Andrew Wilson and Nicole Isbel from Australia.

An international distinguished faculty from around the globe will join us later this month in Brisbane, Australia. An exceptional program with outstanding learning objectives has been prepared for you!

...

It is not too late to register - Registration is still open!
www.clinical-lipidology.com

See More
The conference is aimed at health care professionals, who would like to increase their knowledge in lipid disorders. Brisbane, Australia from 10-12.2.2017
clinical-lipidology.com
Posts

The Clinical Lipidology Congress is around the Corner…

We have been working vigorously to create an interesting and stimulating program for the upcoming Clinical Lipidology Congress.

The Scientific Program incorporates all aspects of lipid disorders from diagnosis to treatment, from diet to novel lipid lowering drugs, from adverse events to compliance issues. The program was specifically designed to facilitate productive discussions and provide opportunities for the participa...nts to present their work.

It is not too late to register - Registration is still open!
www.clinical-lipidology.com

See More
The conference is aimed at health care professionals, who would like to increase their knowledge in lipid disorders. Brisbane, Australia from 10-12.2.2017
clinical-lipidology.com

Advance your skills! Register today.
www.clinical-lipidology.com

Familial Hypercholesterolemia, or FH, is a genetic cholesterol disorder often leading to premature heart attacks, stents, or even death. Afflicted young families face circumstances ordinarily reser…
thefhfoundation.org

We are delighted to announce that Dr. Warrick Bishop will discuss "Plaque Assessment in Clinical Practice" at the 3rd World Congress on Clinical Lipidology.

Dr. Bishop is a practicing cardiologist with an interest in cardiovascular disease prevention and a special interest in eating guidelines, cardiac CT imaging and lipid management.

He is a member of the Australian Atherosclerosis Society and a participant on the panel of 'interested parties' developing a model of care and ...national registry for Familial Hypercholesterolaemia. He has also developed a particular interest in diabetic-related risk of coronary artery disease, specifically related to eating guidelines and lipid profiles.

See More
Image may contain: 1 person, smiling, suit, eyeglasses and closeup

We are proud to announce that Mater Pathology will be exhibiting at the 3rd World Congress on Clinical Lipidology.

Mater Pathology is a fully accredited not-for-profit pathology service established in 1919 by the Sisters of Mercy in Brisbane. As a multi-faceted and technologically advanced laboratory, we have sought-after experience in highly complex pathology including massively parallel sequencing of genes associated with dyslipidaemias and inherited cardiac conditions. We analyse a targeted Illumina panel of 11 genes for dyslipidaemia (ABCG5, ABCG8, APOB, APOC2, APOE, GPIHBP1, LDLR, LDLRAP1, LMF1, LPL, PCSK9) with a 70-80% diagnosis rate for Familial Hyperlipidaemia.

Have you registered yet? www.clinical-lipidology.com

The conference is aimed at health care professionals, who would like to increase their knowledge in lipid disorders. Brisbane, Australia from 10-12.2.2017
clinical-lipidology.com

What are the New Dietary Fats?

Register today and meet Prof. Paul Nestel from Baker IDI Heart & Diabetes Institute, Australia
www.clinical-lipidology.com
#LIPIDS2017 #lipidology #cardiology #diabetes

The conference is aimed at health care professionals, who would like to increase their knowledge in lipid disorders. Brisbane, Australia from 10-12.2.2017
clinical-lipidology.com

Patients with coronary disease who were treated with evolocumab achieved lower LDL-C levels and greater plaque reduction, trial results show.

Want to know more?
Register today – www.clinical-lipidology.com
#lLIPIDS2017 #PCSK9

Patients with coronary disease who were treated with evolocumab achieved lower LDL-C levels and greater plaque reduction, trial results show.
pharmaceutical-journal.com

Will you be joining us in February 2017?
www.clinical-lipidology.com
#LIPIDS2017 #lipids #diabetes

High triglycerides – a type of fat, or lipid, in the blood – increase the risk of heart disease and perhaps type 2 diabetes. For the first time, it has been shown that profoundly lowering triglycerides in diabetics improves their insulin sensitivity over time, which helps them maintain healthy gluco...
knowridge.com

Prof. Philip Barter from the University of New South Wales will discuss "HDL: Risk Marker or Therapeutic Target?" at the 3rd World Congress on Clinical Lipidology.

Join him, register today – www.clinical-lipidology.com
#LIPIDS2017 #HDL #atherosclerosis #lipids #cardiovascular

The conference is aimed at health care professionals, who would like to increase their knowledge in lipid disorders. Brisbane, Australia from 10-12.2.2017
clinical-lipidology.com

The use of the PCSK9 inhibitor alirocumab to achieve larger reductions in LDL and lower on-treatment LDL was linked to lower incidence of major adverse CV events compared with other treatment strategies, according to a post-hoc analysis published in Circulation.

Take advantage of the Christmas Special by registering today
www.clinical-lipidology.com

The use of the PCSK9 inhibitor alirocumab to achieve larger reductions in LDL and lower on-treatment LDL was linked to lower incidence of major adverse CV events compared with other treatment strategies, according to a post-hoc analysis published in Circulation. “Experts have been uncertain wh...
healio.com

Keep yourself informed with the latest developments for PCSK9.

Remember to finalise your registration before the holidays
www.clinical-lipidology.com
#LIPIDS2017 #dyslipidaemia #PCSK9 #endocrinology

Article preview View full access options Nature Reviews Endocrinology | Research Highlight Print Share/bookmark Cite U Like Facebook Twitter Delicious Digg Google+ LinkedIn Reddit StumbleUpon Previous article Nature Reviews Endocrinology | Research Highlights Obesity: Obesity alters fatty acid sensi...
nature.com

Join us for the leading gathering on Clinical Lipidology in Brisbane, Australia from 10-12 February 2017.
www.clinical-lipidology.com
#LIPIDS2017 #hypertension #lipids

Most doctors already know "if their patient can't afford their medicines or their food, this is going to make it harder to manage their illness, but they probably didn't know what they can do about it."
medscape.com

Christmas Special: Registration Discount off the Standard Rates
Valid from 19 - 26 December, 2016 for new participants only

Click on the registration link address to register.
https://events.eventact.com/runreg2/event/RegForm.aspx…...
#LIPIDS2017 #atherosclerosis #cardiology #cardiovascular #HDL

See More
Image may contain: text

Prof. Stephen Nicholls from the University of Adelaide will talk about "Plaque Quantification and Atherosclerosis Regression" at the 3rd World Congress on Clinical Lipidology.

Do not miss the opportunity. Register today!
www.clinical-lipidology.com
#LIPIDS2017 #atherosclerosis #cardiology #cardiovascular #HDL

Image may contain: 1 person, smiling

Lipoprotein(a): Another Emergent Target for PCSK9 Inhibitors?

Find out more in Brisbane from 10-12 February, 2017!
Book your spot now – www.clinical-lipidology.com
#LIPIDS2017 #PCSK9 #cardiology

So far, strategies to lower lipoprotein(a), a risk factor for cardiovascular disease, have been unsuccessful. Could PCSK9 inhibitors be the answer?
medscape.com

Meet our PLATINUM Sponsor: Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions ...that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen

Don't miss out by registering today: www.clinical-lipidology.com
#LIPIDS2017 #lipid #cardiology

See More
No automatic alt text available.